Drug firm Zydus Cadila today said it has received US health regulator's nod for marketing Tamsulosin capsules, used for treating problems related to urology, in the US.
Zydus Cadila has received an an approval from the US Food and Drug Administration to market Tamsulosin capsules in 0.4 mg strength, the company said in a filing to Bombay Stock Exchange (BSE).
Tamsulosin falls in the urology segment and is indicated for the treatment of Benign Prostatic Hyperplasia and the drug has reported an estimated sales of $2.79 billion in the US in 2009.
Following this approval, the group has now approvals for 54 products for the US market and has so far filed 106 abbreviated new drug application since the commencement of filing process in the 2003-04 fiscal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app